AKT1 and glioblastoma: Notably, the combination of MET404 antibody and onartuzumab, an FDA-approved MET signalling inhibitor that showed a negative effect in GBM clinical trials11, maximally inhibited MET signalling and downstream events including AKT/ERK activation and cellular viability (Fig. 7d).